|1.||Griffin, James D: 8 articles (12/2008 - 06/2002)|
|2.||Gilliland, D Gary: 7 articles (02/2012 - 06/2002)|
|3.||Roesel, Johannes: 6 articles (12/2013 - 10/2004)|
|4.||Galinsky, Ilene: 6 articles (10/2010 - 10/2004)|
|5.||Wang, Yanfeng: 5 articles (12/2013 - 01/2005)|
|6.||Fabbro, Doriano: 5 articles (12/2005 - 01/2002)|
|7.||Stone, Richard M: 4 articles (10/2010 - 10/2004)|
|8.||Ehninger, Gerhard: 4 articles (10/2010 - 01/2006)|
|9.||Stone, Richard: 4 articles (07/2010 - 07/2005)|
|10.||Weisberg, Ellen: 4 articles (07/2010 - 06/2002)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
07/01/2010 - "Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells."
07/01/2007 - "PKC412 has proven activity in the treatment of acute myelogenous leukemia (AML). "
05/15/2004 - "Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3."
07/01/2007 - "Another promising therapeutic target, FLT3, is mutated in about one third of acute myelogenous leukemia (AML) patients; promising results have recently been achieved in clinical trials investigating the effects of the protein tyrosine kinase inhibitor PKC412 on AML patients harboring mutations in the FLT3 protein. "
07/01/2010 - "Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation."
01/01/2013 - "Interestingly, Flt3 deficient leukemia samples also displayed some sensitivity to PKC412. "
01/01/2013 - "As previously reported for human MLL-rearranged leukemias, murine MLL-ENL leukemia cells with higher Flt3 levels were more sensitive to the cytotoxicity of PKC412. "
01/01/2013 - "To determine the anti-leukemic effect of FLT3 inhibition we studied the sensitivity of MLL-ENL leukemia cells to the FLT3 inhibitor PKC412 ex vivo. "
05/01/2007 - "Cell-cycle analysis revealed that PKC412 induced G1 arrest in leukemia cell lines carrying FLT3 mutations, whereas it arrested cells in G2/M phase in the absence of FLT3 mutations, which may underlie the divergent cytotoxic interactions. "
05/01/2007 - "Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines."
06/01/2005 - "PKC412 is an appropriate candidate for novel treatment protocols for multiple myeloma."
02/15/2007 - "PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells."
02/15/2007 - "The effect and mode of action of the protein kinase C (PKC) inhibitor PKC412 on human multiple myeloma (MM) cell lines (HMCLs) and primary MM cells was explored. "
06/01/2005 - "N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells."
|4.||Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/01/2015 - "PKC412 induced apoptosis in a subset of TNBC cells enriched for the basal-like subtype and inhibited tumor growth in vivo. "
01/01/2014 - "This is the first report of a high-tumor-load MCL case which achieved prolonged survival (101 months) by PKC 412. "
10/01/2007 - "In vivo PKC412 therapy resulted in a significant inhibition of orthotopic tumor growth with abrogation of tumor angiogenesis. "
01/01/2006 - "At autopsy, we found that PKC412 itself slightly reduced the mass of tumor but did not fully inhibit tumor formation. "
03/01/2003 - "PKC412 (200 mg/kg) administered orally for four weeks after the tumor inoculation, significantly prolonged survival compared with the control. "
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Protein Kinase C
|5.||Protein Kinases (Protein Kinase)
|10.||4- (6- methoxy- 7- (3- piperidin- 1- ylpropoxy)quinazolin- 4- yl)piperazine- 1- carboxylic acid (4-isopropoxyphenyl)amide
|5.||Heterologous Transplantation (Xenotransplantation)